PRQR

ProQR Therapeutics N.V. Ordinary Shares

1.49

USD

PRQR Earnings Reports

Positive Surprise Ratio

PRQR beat 29 of 40 last estimates.

73%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$4.50M

-$0.11

Implied change from Q4 25 (Revenue/ EPS)

-3.96%

+37.50%

Implied change from Q1 25 (Revenue/ EPS)

-0.37%

+10.00%

ProQR Therapeutics N.V. Ordinary Shares earnings per share and revenue

On Mar 12, 2026, PRQR reported earnings of -0.08 USD per share (EPS) for Q4 25, beating the estimate of -0.10 USD, resulting in a 18.84% surprise. Revenue reached 4.69 million, compared to an expected 3.88 million, with a 20.70% difference. The market reacted with a -2.04% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 4.50 million USD, implying an increase of 37.50% EPS, and decrease of -3.96% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were ProQR Therapeutics N.V. Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, ProQR Therapeutics N.V. Ordinary Shares reported EPS of -$0.08, beating estimates by 18.84%, and revenue of $4.69M, 20.7% above expectations.

How did the market react to ProQR Therapeutics N.V. Ordinary Shares's Q4 2025 earnings?

The stock price moved down -2.04%, changed from $1.47 before the earnings release to $1.44 the day after.

When is ProQR Therapeutics N.V. Ordinary Shares expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for ProQR Therapeutics N.V. Ordinary Shares's next earnings report?

Based on 6 analysts, ProQR Therapeutics N.V. Ordinary Shares is expected to report EPS of -$0.11 and revenue of $4.50M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.